Jianfeng Group Lin2016 -032 (Announcement on Main Operating Data of the Company in the Third Quarter of 2016)
Release time:
2020-08-05
证券代码：600668 证券简称：尖峰集团 公告编号：2016-032
债券简称：13尖峰01 债券代码：122227
债券简称：13尖峰02 债券代码：122344
浙江尖峰集团股份有限公司
关于公司2016年三季度主要经营数据的公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。
根据上海证券交易所发布的上市公司分行业信息披露指引《上市公司行业信息披露指引第七号——医药制造》及《关于做好上市公司2016年三季度报告披露工作的通知》相关要求，因公司目前涉及医药制造行业，现将公司2016年三季度主要经营数据披露如下：
一、报告期内分行业经营数据
单位：万元币种：人民币
|
行业 |
主营业务收入 |
主营业务成本 |
毛利率 |
|||||||
|
2016年1-9月 |
2015年1-9月 |
增长率（%） |
2016年1-9月 |
2015年1-9月 |
增长率（%） |
2016年1-9月（%） |
2015年1-9月（%） |
增减百分点 |
||
|
水泥行业 |
64,226.70 |
65,057.19 |
-1.28 |
46,017.89 |
51,686.93 |
-10.97 |
28.35 |
20.55 |
增加7.80个百分点 |
|
|
医药行业 |
75,880.36 |
72,988.68 |
3.96 |
63,424.48 |
60,844.01 |
4.24 |
16.42 |
16.64 |
减少0.22个百分点 |
|
|
健康品行业 |
13,168.77 |
10,365.15 |
27.05 |
9,405.50 |
6,810.62 |
38.10 |
28.58 |
34.29 |
减少5.71个百分点 |
|
|
其他行业 |
11,148.14 |
12,447.12 |
-10.44 |
9,733.73 |
11,131.24 |
-12.55 |
12.69 |
10.57 |
增加2.12个百分点 |
|
|
合计 |
164,423.97 |
160,858.14 |
2.22 |
128,581.60 |
130,472.80 |
-1.45 |
21.80 |
18.89 |
增加2.91个百分点 |
|
二、报告期内分产品经营数据
单位：万元币种：人民币
|
产品 |
主营业务收入 |
主营业务成本 |
毛利率 |
|||||||
|
2016年1-9月 |
2015年1-9月 |
增长率（%） |
2016年1-9月 |
2015年1-9月 |
增长率（%） |
2016年1-9月（%） |
2015年1-9月（%） |
增减百分点 |
||
|
水泥 |
64,226.70 |
65,057.19 |
-1.28 |
46,017.89 |
51,686.93 |
-10.97 |
28.35 |
20.55 |
增加7.80个百分点 |
|
|
医药工业产品 |
14,069.08 |
13,612.32 |
3.36 |
5,133.02 |
4,514.28 |
13.71 |
63.52 |
66.84 |
减少3.32个百分点 |
|
|
医药商业产品 |
61,811.28 |
59,376.36 |
4.10 |
58,291.46 |
56,329.73 |
3.48 |
5.69 |
5.13 |
增加0.56个百分点 |
|
|
健康品 |
More information Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution 2020 07-31 Spike New Drug Approved for Registration On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin) 2020 07-31 Spike New Drug Approved for Registration On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin) 2020 07-31 Contact Us 
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China 
Tel: +86-579-82326868 
Fax : +86-579-82324666 
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
| |||||||||
